tiprankstipranks
Incyte Corp (INCY)
NASDAQ:INCY
US Market
INCY
Incyte
RESEARCH TOOLSreports

Incyte (INCY) Stock News & Sentiment

1,917 Followers
Incyte Announces Upcoming Resignation of Board Member Schaffert
Premium
Company Announcements
Incyte Announces Upcoming Resignation of Board Member Schaffert
13d ago
8K
INCY
Incyte Announces Major Executive Leadership and Commercial Reorganization
Premium
Company Announcements
Incyte Announces Major Executive Leadership and Commercial Reorganization
17d ago
8K
INCY
Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial
Premium
Company Announcements
Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial
24d ago
INCY
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing
Premium
Company Announcements
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing
1M ago
INCY
Incyte’s Ruxolitinib Pediatric Leukemia Study Update: What Investors Should Watch
Premium
Company Announcements
Incyte’s Ruxolitinib Pediatric Leukemia Study Update: What Investors Should Watch
1M ago
INCY
Balancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte
Premium
Ratings
Balancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte
1M ago
INCY
Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion
Premium
Company Announcements
Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion
1M ago
8K
INCY
More INCY News >

INCY News on the Web

Incyte price target raised to $95 from $92 at RBC Capital
TipRanks News
Neutral
Incyte (INCY) Receives a Hold from Wells Fargo
TipRanks News
Neutral
Baker Bros. Advisors LP Increases Stake in Celcuity Inc.
GuruFocus News
Neutral
Incyte Corporation (INCY) Announces Board Member Resignation
GuruFocus News
Neutral
Incyte Announces Upcoming Resignation of Board Member Schaffert
TipRanks News
Neutral
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
Zacks
Bullish
Analysts Offer Insights on Healthcare Companies: Lipocine (LPCN), Viridian Therapeutics (VRDN) and Incyte (INCY)
TipRanks News
Neutral
Guggenheim Sticks to Their Buy Rating for Incyte (INCY)
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
INCY
Sector Average
Media Buzz
This Week2 articles
Weekly Average6.75 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is INCY’s Media Buzz Sentiment?
2 articles about INCY were published this week. In an average week, 6.75 articles are published.
    What is INCY’s weekly average amount of articles?
    In an average week, 6.75 articles about INCY are published.
      What is INCY’s News Sentiment?
      100% of articles about INCY were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week